利用18F-FDG PET/CT衍生的身体成分特征预测非小细胞肺癌淋巴血管侵犯
该研究回顾性分析248例早期非小细胞肺癌患者(维也纳训练队列153例,布达佩斯验证队列95例),利用术前18F-FDG PET/CT评估肿瘤代谢参数及身体成分特征,构建列线图预测淋巴血管侵犯。列线图在验证队列中AUC为0.790,且预测的淋巴血管侵犯与更差的3年无复发生存和5年生存显著相关。
要点
- 列线图结合MTV、N分期和身体成分特征,在布达佩斯验证队列中AUC为0.790。
- 列线图预测的淋巴血管侵犯与显著更差的3年无复发生存和5年生存相关。
- 列线图显著优于仅基于临床变量(p=7.92e-06)或仅基于影像变量(p=0.0474)的模型。
核心结论
- 整合PET/CT身体成分、临床和肿瘤代谢特征可在术前预测非小细胞肺癌的淋巴血管侵犯,支持改进风险分层。
研究设计与样本
- 回顾性分析248例患者,包括维也纳训练队列153例和布达佩斯验证队列95例。
- 使用术前18F-FDG PET/CT评估肿瘤代谢参数(SUVmax、SUVmean、MTV、TLG)及身体成分特征(L1-L5内脏、皮下、肌间脂肪组织和骨骼肌)。
- 采用LASSO回归筛选关键身体成分特征,构建基于逻辑回归的列线图,并通过ROC分析、校准、决策曲线分析和生存分析进行验证。
主要发现
- 淋巴血管侵犯在维也纳患者中为66/153(43.1%),在布达佩斯患者中为39/95(41.1%)。
- 基于维也纳训练队列开发的列线图(纳入MTV、N分期和身体成分)在布达佩斯验证队列中AUC为0.790。
- 统计检验证实列线图显著优于仅基于临床变量(p=7.92e-06)或仅基于影像变量(p=0.0474)的模型。
- 列线图预测的淋巴血管侵犯与显著更差的3年无复发生存和5年生存相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Lymphovascular invasion (LVI) in non-small cell lung cancer (NSCLC) is a critical prognostic marker linked to higher risks of metastasis and recurrence. This study aimed to develop a non-invasive predictive model using body composition features from 18F-FDG PET/CT imaging to assess LVI risk in early-stage NSCLC patients. METHODS: We retrospectively analyzed 248 patients, including 153 from Vienna (training cohort) and 95 from Budapest (validation cohort). Preoperative 18F-FDG PET/CT scans were used to assess tumor metabolic parameters, including standardized uptake values (SUVmax, SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG), as well as body composition features, including visceral, subcutaneous, and intermuscular adipose tissue, skeletal muscle at L1-L5. LASSO regression identified key body composition features, and a logistic regression-based nomogram was constructed and validated through ROC analysis, calibration, decision curve analysis, and survival analysis. RESULTS: LVI was present in 66/153 (43.1%) of Vienna and 39/95 (41.1%) of Budapest patients. The nomogram, developed using the Vienna training cohort, incorporating MTV, N stage, and body composition achieved an AUC of 0.839 and 0.790 in the Budapest validation cohort. Statistical tests confirmed that the nomogram significantly outperformed models based on either clinical (p = 7.92e-06) or imaging variables alone (p = 0.0474). Furthermore, LVI predicted by the nomogram was associated with significantly poorer 3-year recurrence-free and 5-year survival. CONCLUSION: Integrating body composition with clinical and tumor metabolic features from PET/CT enables preoperative prediction of LVI in NSCLC, supporting improved risk stratification.
引用
- Jiang Z, Haberl D, Spielvogel C, et al. Using 18F-FDG PET/CT-derived body composition features to predict lymphovascular invasion in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2025. PMID: 40699302. doi:10.1007/s00259-025-07435-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。